{"id":"NCT04193527","sponsor":"GE Healthcare","briefTitle":"A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients","officialTitle":"A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-28","primaryCompletion":"2021-12-20","completion":"2021-12-20","firstPosted":"2019-12-10","resultsPosted":"2023-10-16","lastUpdate":"2023-10-16"},"enrollment":172,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Parkinsonian Syndrome","Parkinson Disease(PD)","Multiple System Atrophy (MSA)","Progressive Supranuclear Palsy (PSP)","Essential Tremor"],"interventions":[{"type":"DRUG","name":"DaTSCAN™ Ioflupane (123I) Injection","otherNames":["Ioflupane (123I)"]}],"arms":[{"label":"DaTSCAN™ ioflupane (123I) injection","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical diagnosis of Parkinsonian syndrome (PS) involving striatal dopaminergic deficit (SDD; specifically, Parkinson's disease \\[PD\\] \\[SDD\\], multiple system atrophy \\[MSA\\] \\[SDD\\] or or progressive supranuclear palsy \\[PSP\\] \\[SDD\\]) as compared with patients with a clinical diagnosis of essential tremor (ET) (no SDD) and age-matched healthy controls.","primaryOutcome":{"measure":"Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT Images","timeFrame":"At Day 1","effectByArm":[{"arm":"DaTSCAN™ Ioflupane: Participants With Parkinsonian Syndrome (PS)","deltaMin":0.851,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":75},"commonTop":["Paraesthesia","Urinary tract infection","Blood glucose increased","Blood creatine phosphokinase increased","Protein urine present"]}}